Results 101 to 110 of about 24,049 (149)

Evaluating the toxicity profile of combination immune checkpoint inhibitors: a disproportionality analysis of real-world adverse events from the FDA Adverse Event Reporting System for tremelimumab, durvalumab, ipilimumab, and nivolumab. [PDF]

Front Immunol
Li Z, Xie Y, Wang T, Liu Y, Tian Y, Hua Y.   +5 more
europepmc   +1 more source

Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial. [PDF]

J Gynecol Oncol
Nishio S, Nishikawa T, Mori M, Kamiura S, Sumi T, Yunokawa M, Imai Y, Kondo E, Takehara K, Takano H, Kudaka W, Kado N, Yamagami W, Kato H, Nishino K, Usami T, Hamanishi J, Nii M, Takaya I, Okamoto A.   +19 more
europepmc   +1 more source

Clinical management of liver cancer patients with immune checkpoint inhibitors treatment. [PDF]

Hepat Oncol
Yau JCW, Chan LL, Chan SL.
europepmc   +1 more source

Novel use of carboplatin, etoposide and durvalumab as neoadjuvant therapy in treatment of small cell bladder cancer. [PDF]

Urol Case Rep
Gonzalez V, Linton E, Boyce T, Dahmoush L, Hougen HY.   +4 more
europepmc   +1 more source

Early checkpoint inhibition before chemoradiation: is the strategy ready for stage III non-small cell lung cancer? [PDF]

Transl Lung Cancer Res
Hasan N, Harris JP, Nagasaka M.
europepmc   +1 more source

Durvalumab With or Without Tremelimumab in Combination With Chemoradiotherapy in Patients With Limited-Stage SCLC: Results from the Phase 1 CLOVER Study. [PDF]

JTO Clin Res Rep
Cho BC, Ahn MJ, Nishio M, Murakami H, Wan-Kim D, Kim SW, Karam SD, Estival A, Lin CC, Trigo JM, Alvarez R, Wang CL, Xie M, Iyer S, Armstrong J, Chugh P, Jiang H, Bauman JE.   +17 more
europepmc   +1 more source

TDM-Based Tailored Dosing of Durvalumab in Lung Cancer Patients: A Comprehensive Population Pharmacokinetic-Pharmacoeconomic Evaluation. [PDF]

Clin Pharmacokinet
de Vries F, Franssen EJF, Smit AAJ, Moes DJAR, van der Wekken AJ, Munnink TO, Hendrikx JJMA, Dumoulin DW, Koolen SLW, Kievit W, van den Heuvel MM, Ter Heine R.   +11 more
europepmc   +1 more source

Unresectable hepatocellular carcinoma effectively treated with durvalumab and tremelimumab after splenectomy: a case study

Yuta Koga, Akifumi Kuwano, Shigehiro Nagasawa, Masatake Tanaka, Masayoshi Yada, Akihide Masumoto, Kenta Motomura   +6 more
openalex   +1 more source

The efficacy of durvalumab in locally advanced lung carcinoma

I. Kneževic, Stefan Raskov, Miodrag Djordjević, Bojan Zarić   +3 more
openalex   +1 more source